[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Makerere University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":282},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,66,93,121,144,167,193,213,236,260],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638567","evaluation-of-an-information-management-and-communication-system-for-population-wide-point-of-care-infant-sickle-cell-disease-screening-100638567",false,"NCT07610239","Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening","SMICS","Inclusion Criteria:\n\nProviders of child health and maternity services at selected hospitals Infants born or attending child health and maternity services at selected hospitals . Infants are the targeted age-group in this study because this is the ideal age to screen for SCD and prevent complications and mortality that generally occurs early, by 5 years old. The infants will be recruited at birth or at vaccination visits\n\nExclusion Criteria:\n\n* Decline of inability to provide informed consent",true,"ALL","18 Years",{"count":20,"type":21},24000,"ESTIMATED","INTERVENTIONAL",[24],"NA","A cluster randomized trial (CRT) of the novel sickle cell disease (SCD), M-health based SCD Information Management and Communication system SIMCS vs routine new born screening strategy in health care centres in Uganda to evaluate impact on access screening, coordination of care and clinical outcomes",[27],"Sickle Cell Disease","RECRUITING","2026-05-20",{"date":31,"type":32},"2026-05-27","ACTUAL",{"date":34,"type":32},"2026-03-25",{"date":36,"type":21},"2027-06-30",{"name":38,"class":39},"Makerere University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100358314","phase-2-single-dose-liposomal-amphotericin-for-asymptomatic-cryptococcal-antigenemia-100358314","NCT03945448","Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia","Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons","ACACIA","Inclusion Criteria:\n\n* HIV-1 infection\n* Age \\> or equal to15 years\n* Ability and willingness to give informed consent.\n* Plasma\u002FSerum cryptococcal antigen (CRAG)+ with a titer 1:160 or greater\n\nExclusion Criteria:\n\n* Cannot or unlikely to attend regular clinic visits\n* History of cryptococcal infection\n* Symptomatic meningitis (confirmed by CSF CRAG+)\n* \\>14 days of fluconazole therapy\n* Pregnancy (confirmed by urinary or serum pregnancy test)\n* Current breastfeeding\n* Known allergy to amphotericin","15 Years",{"count":51,"type":21},356,[53,54],"PHASE2","PHASE3","This will be a randomized controlled trial of asymptomatic (Cryptococcal Antigen test)CrAg positive persons in Uganda.\n\nPatients will be randomized to receive preemptive treatment with 1 dose of liposomal amphotericin (10mg\u002Fkg) in addition to standard of care fluconazole therapy.\n\nHow the enhanced antifungal therapy prevents progression to meningitis in the first 24-weeks and overall survival in those who receive the intervention compared with participants receiving fluconazole per World Health Organisation (WHO) and national standard of care therapy will be evaluated.",[57],"Cryptococcal Meningitis","2026-04-27",{"date":60,"type":32},"2026-04-28",{"date":62,"type":32},"2019-06-20",{"date":64,"type":21},"2027-08",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100624302","call-for-life-sepsis-100624302","NCT07407868","Call for Life Sepsis","Evaluating The Impact on 90-day Survival Of Post-Discharge Follow-up Strategies Delivered To Adult Patients Hospitalized With Sepsis Across A Research Network In Sub-Saharan Africa","C4L-Sepsis","Inclusion Criteria:\n\n* At admission\n\n  1. Adults ≥18 years.\n  2. Participant's hospital admission diagnosis is consistent with the following broad definition of sepsis, incorporating its principal components (signs of infection plus signs of severity\u002Forgan dysfunction):\n\n     1. Signs of infection: Suspected or proven infection, as determined by the medical team in charge.\n     2. Illness severity: Decision of the medical team to admit the patient to an adult medical ward of the study hospital, according to clinical appraisal of the treating physician and applicable guidelines.\n  3. Participant\u002Fproxy is willing to have their medical records reviewed by the trial team and get daily follow-ups until the time of discharge and to be approached again by the study team for a second informed consent process towards the time of hospital discharge.\n  4. Evidence of a personally signed and dated informed consent form stating that the participant\u002Fproxy has been informed of, had opportunity to ask questions about and have consented to the initial study procedures that will be conducted during their hospitalization. At discharge\n  5. Patient has overcome the critically ill phase of their hospitalization and is, according to the non-study clinical team caring for the patient, expected to be discharged within the next 24 hours.\n  6. Participant is willing and able to comply with scheduled phone follow-ups, and other study procedures.\n  7. Evidence of a personally signed and dated informed consent form stating that the participant has been informed of, had opportunity to ask questions about and have consented to all procedures that will be conducted at the time of and after their discharge, and alternatives and risks for the study.\n  8. The participant confirms that there is availability of mobile network coverage in their place of residence.\n\nExclusion Criteria:\n\nAt Admission;\n\n1. Patient who requires hospitalization for a condition that requires emergent or urgent obstetric or surgical intervention (including burns, trauma, abscess)\n2. Persons who are currently or have been previously enrolled into this study.\n3. Patient is terminally ill due to an underlying condition other than sepsis.\n4. The patient is a detainee or prisoner.\n5. The patient is unable to speak English and Luganda.\n\n   * At Discharge:\n\n   At discharge\n6. The patient is unable to hear.\n7. Participant states they will be unable to return to same health facility for the scheduled 14-day post-discharge clinic assessment (provided by the non-study clinical team)\n8. Patients requiring clinical care for more than 10 days (if clinical care was completed and participant is ready for discharge but are still in hospital for financial or logistical reasons beyond 10 days, they can still be eligible)",{"count":75,"type":21},1410,[24],"Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis-attributable mortality in sub-Saharan Africa (sSA) is high, with in-hospital mortality in some settings approaching 40%. Studies show that mortality among children under 5 years hospitalized with sepsis remains high within the first 6 months of discharge. Additionally, high mortality has been observed among other populations within sSA, with factors such as HIV infection being associated with increased risk. Reducing sepsis deaths contributes to the achievement of the Sustainable Development Goals (SDG), particularly SDG 3 in reducing maternal mortality (3.1), neonatal and under five mortality (3.2), and burden of mortality from communicable diseases (3.3) and improving universal health coverage (3.8). The World Health Organization (WHO) has recognized sepsis as a global priority, with low- and middle-income settings being particularly affected. In sSA, sepsis is commonly associated with infectious diseases like malaria, Human Immunodeficiency Virus\u002F Acquired Immunodeficiency Syndrome (HIV\u002FAIDS), pneumonia, tuberculosis, and diarrhea. Guidelines from the Surviving Sepsis Campaign (SSC) have become standard in some settings. However, little is known about patients' status post-discharge. This study aims to evaluate two post-discharge follow-up strategies for adult sepsis patients. Study duration is 45 months, participants will receive intervention up to 90 days post discharge.\n\nDescription of intervention: Post-discharge follow-up strategy 1: Enhanced Discharge Intervention (EDI) Post-discharge follow-up strategy 2: EDI plus Interactive Voice Response (IVR)\n\nObjectives:\n\nThe study aims to evaluate two post-discharge follow-up strategies for adult patients hospitalized with sepsis, focusing on their efficacy in reducing the 90-day mortality, and their effect on return to follow-up, number of re-admissions, and quality of life.\n\nPrimary efficacy endpoint\n\n* 90- day all-cause mortality post discharge Secondary end points\n* Time to death\n* 28-day all-cause mortality\n* Attendance within 14-day check-up post discharge\n* Re-admission within 28 and 90 days\n* Days alive and out of hospital (DAOH)\n* Quality of life score (Baseline vs 28 day and Baseline vs 90 days)\n* Differences in baseline demographic and clinical characteristics (e.g., age, sex, disease severity, comorbidities, key laboratory values) between randomized participants and screen failures. Study design: This is an open-label, randomized, parallel, interventional study, with two post-discharge follow-up strategies: 1) EDI; or 2) EDI plus IVR system. Fixed allocation randomization at a 1:1 ratio will be applied to either study arm.\n\nSample size: A total of 1,410 (705 per arm) from the four countries (Uganda, Nigeria, Ghana and Mozambique) will be enrolled competitively across the sites.",[79],"Sepsis",[81,82,83],"Reduce post discharge sepsis mortality,","Interactive Voice Response System,","Call for life - IVR","NOT_YET_RECRUITING","2026-02-17",{"date":87,"type":32},"2026-02-19",{"date":89,"type":21},"2026-03-15",{"date":91,"type":21},"2028-06-15",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100568192","use-of-unmanned-air-vehicles-medical-drones-to-overcome-geographical-barriers-to-delivery-of-anti-retroviral-therapy-and-biological-samples-100568192","NCT06678022","Use of Unmanned Air Vehicles (Medical Drones) to Overcome Geographical Barriers to Delivery of Anti-Retroviral Therapy and Biological Samples","Use of Unmanned Air Vehicles (Medical Drones) to Overcome Geographical Barriers to Delivery of Anti-Retrovical Samples: A Cluster Randomised Trial in Kalangala District, Uganda","MRC-DRONES","Inclusion Criteria:\n\n* Adult (\\>18 years) living with HIV\n* Emancipated minor (15-17 years) who is living with HIV\n* Receiving antiretroviral therapy in Kalangala District\n* Be a resident in Kalangala district for at least the preceding 6-12 months\n* Willing to stay for a minimum next 24 months\n* Willing to disclose HIV status to an expert peer or village health team member.\n* Willing to join discentralised Service Delivery model groups\n\nExclusion Criteria:\n\n* Potential participants below 15 years with care providers not receiving care from DSD.\n* No active opportunistic infection (including but not limited to TB) in health centre records or self-report or suspected by the study team at enrolment (will be referred back to health facility for investigations and can be enrolled if no infection confirmed).\n* Patients with mental illness or any other medical condition that compromises decision making process (as determined by medical records at facility and direct questioning to participant)\n* Any other clinical condition that, in the opinion of the site investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.\n* For stage three, participants residing in areas that took part in stage 2 drone delivery eg Bufumira island",{"count":102,"type":21},1086,[24],"The goal of this clinical trial is to learn if the intervention of delivery of antiretroviral drugs by medical drones can improve virological suppression in a fisherfolk community population living with HIV in the islands of Kalangala District, Uganda. The main question it aims to answer is:\n\nCan delivery of anti-retroviral therapy (ART) by unmanned aerial vehicles (medical drones) to people living with HIV (PLHIV) improve virological outcomes compared to the standard of care (SOC) in an underserved population? Primary hypothesis: The investigators hypothesize that using drones will increase viral suppression in those receiving the intervention as compared to the control or outcome measure one-will be the proportion of PLHIV with undetectable HIV viral load in the intervention (drones) versus SOC arm at 12 months.\n\nIf there is a comparison group: Researchers will compare \\[Medical Drones delivery group\\] to see total cost of 12 months medication delivery to people living with HIV (PLHIV) in the intervention as compared to standard of care (SOC) arm.\n\nProportion PLHIV with an undetectable viral load at 6, 18 and 24 months in intervention Rates of retention in care of PLHIV at 6,12, 18 and 24 months in intervention as compared to SOC arm\n\n* Participants will be seen every 6 months for 24 months\n* They will have blood draws for viral load tests\n* They will complete interviewer administered questionnaires\n* The intervention is last-mile delivery of ART by drones to landing sites",[106,107],"HIV","Viral Load",[109,110,111,112],"virological suppression","Fisher Folk","Cluster Randomised Trial","medical drones","2026-02-12",{"date":85,"type":32},{"date":116,"type":32},"2025-03-18",{"date":118,"type":21},"2027-12-15",{"name":38,"class":39},2,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100591072","enhancing-comprehension-of-consent-in-patients-with-psychotic-disorders-100591072","NCT06975670","Enhancing Comprehension of Consent in Patients With Psychotic Disorders","ENHANCING COMPREHENSION OF INFORMED CONSENT IN RESEARCH INVOLVING PATIENTS WITH PSYCHOTIC DISORDERS USING AUDIO-VISUAL AIDS","UBACC","Inclusion Criteria:\n\n* Psychotic disorders who score below 14.5 on UBACC trials.\n* 18-60 years\n\nExclusion Criteria:\n\n* Those participants that do not speak English or Luganda will be excluded from the study\n* Hearing or Visual impairments","60 Years",{"count":131,"type":21},60,[24],": Informed consent is an important aspect of research, however in psychiatry research it remains an ethical dilemma, for the lack of clarity on the consent process deters some researchers from mental health research, and yet a good research must ensure that this moral stand is undertaken. Studies that literally test measures that improve the informed consent process in participants with psychotic disorders have been scanty. To date, there is a noticeable absence of an evidence-based intervention for enhancing the comprehension of consent information in research participants with psychotic disorders in the Ugandan context. Thus, this research study is to explore methods like incorporating multimedia components, such as audio and visual aids, to enhance the participants' grasp of research particulars, thereby enabling them to make informed decisions effectively and give informed consent when they are invited to participate in research projects.\n\nObjective: To evaluate the comprehension of informed consent, identify key factors that that are associated with comprehension of consent, and determine the feasibility, acceptability, and preliminary effectiveness of audio-visual aids on enhancing the comprehension of consent information during the consenting process in research involving individuals with psychotic disorders.\n\nMethods: This will be a multi-method research design that will be achieved through four sub-studies. Sub-study 1 will be cross-sectional and will involve an assessment of comprehension of informed consent using the University of California Brief Assessment of Capacity to Consent (UBACC) tool. Participants will be patients aged 18- 60 years with a psychotic disorder. Sub-study 2 will be a qualitative study that utilizes a user-centered design approach by engaging a multidisciplinary team of stakeholders to develop a multimedia audio-visual consent tool.\n\nSub-study 3 will be a randomized pilot study designed to evaluate the effectiveness of the multimedia video consent tool and how it compares with the traditional paper method in enhancing participants' comprehension of consent information.\n\nSub-study 4 will be a mixed-methods approach using quantitative and qualitative data from exit interviews to assess the Feasibility and Acceptability of the audio-visual consent tool for individuals with psychotic disorders and the research assistants administering the tool in a mental health research setting",[135],"Psychosis","2025-05-20",{"date":138,"type":32},"2025-05-23",{"date":140,"type":21},"2025-05-30",{"date":142,"type":21},"2025-08-30",{"name":38,"class":39},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":120},"100552753","phase-2-characterization-of-tuberculosis-associated-lung-fibrosis-and-respiratory-impairment-and-prevention-using-doxycycline-100552753","NCT06477185","Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline","Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline in A Double Blind Randomized Controlled Trial","TALF-TB","Inclusion Criteria:\n\n* Age of 18 - 65 years\n* Index PTB episode (sputum smear positive or GeneXpert positive with rifampicin susceptibility)\n* Baseline CXR showing infiltrates in at least 2 lung zones (≥30% lung involvement) meeting criteria for moderate\u002Fadvanced PTB\n* HIV uninfected\n* Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n* Able to give written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* Breastfeeding\n* Baseline serum creatinine or liver enzymes \\>2 times above upper limit of normal\n* Taking corticosteroids for ≥14 days or anti-TBs \\>7days\n* Prospects already enrolled in another clinical trial\n* Diabetic patients (most diabetics are on metformin or have history of metformin use. Metformin is postulated to have an anti-fibrosis role)\n* Patients with malignancy or on anticancer medication\n* Situation where a participant is taking a drug\u002Fmedication known to interact with the trial drug.\n* Known allergies to doxycycline or other tetracyclines\n* Known autoimmune disease\n* Any factor felt to significantly increase risk of adverse event","65 Years",{"count":154,"type":21},200,[53],"The goal of this clinical trial is to assess the efficacy(effectiveness) of doxycycline, a potent inhibitor of matrix metalloproteinase (lung collagenase) activity in prevention of Tuberculosis associated lung fibrosis and associated lung function decline among patients with drug sensitive advanced TB. The main question\\[s\\] it aims to answer are:\n\n* Does doxycycline have a significant anti-fibrosis role when given as adjuvant therapy to TB patients with advanced pulmonary TB in a double blind randomized placebo controlled trial?\n* How does long term respiratory function defer between patients who received adjuvant doxycycline aimed at prevention of TB associated lung fibrosis and those who received a placebo in a double blind randomized controlled trial?\n\nParticipants will be subjected to the following:\n\n* Experimental arm: Doxycycline 100 mg once daily for 12 weeks administered concurrently with standard of care anti-TBs.\n* Comparator arm: Placebo once daily for 12 weeks administered concurrently with standard of care anti-TBs.",[158],"Tuberculosis, Pulmonary","2025-04-14",{"date":161,"type":32},"2025-04-17",{"date":163,"type":32},"2024-12-04",{"date":165,"type":21},"2027-12",{"name":38,"class":39},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":40},"100584270","multimodal-analgesia-utilization-and-acute-postoperative-pain-after-major-surgery-at-mulago-national-referral-hospital-100584270","NCT06887153","Multimodal Analgesia Utilization and Acute Postoperative Pain After Major Surgery at Mulago National Referral Hospital","Perioperative Multimodal Analgesia Practices and Associated Acute Postoperative Pain in Patients Undergoing Major Surgery at Mulago National Referral Hospital","Inclusion Criteria:\n\n* Patients ≥18 years\n* Scheduled for elective orthopaedic, abdominal and thoracic surgeries\n* In the selected operating theatres during the study period\n\nExclusion Criteria:\n\n* Reduced levels of consciousness or neurological deficits\n* ASA \\>III",{"count":175,"type":21},449,"OBSERVATIONAL","The goal of this observational study is to understand the approach to pain management before, during, and after surgery at Mulago National Referral Hospital. It is focussed on adult patients undergoing major surgery. The main questions it aims to answer are:\n\n* How often are combinations of pain medications utilised before, during and after surgery?\n* Do combinations of pain medications result in better pain control after surgery compared to single pain medications?\n\nInformation on pain medications will be obtained from patient records. Patients will be asked to rate their pain after surgery every 6 hours for 24 hours.",[179],"Pain",[181,182,183,184],"Perioperative","Multimodal Analgesia","Acute Postoperative Pain","Major Surgery","2025-03-23",{"date":187,"type":32},"2025-03-25",{"date":189,"type":32},"2024-08-08",{"date":191,"type":21},"2025-07-17",{"name":38,"class":39},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":120},"100559385","development-and-evaluation-of-an-information-management-system-and-communication-system-for-population-wide-point-of-care-infant-sickle-cell-disease-screening-100559385","NCT06563440","Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening","SIMCS SCD","Inclusion Criteria: A participant will be eligible for enrolment if at baseline they are an infant less than 1 year of age and presents to any of the health centers in the communities where the project will be conducted.\n\nExclusion Criteria: Persons 1 year or older","5 Years",{"count":20,"type":21},[24],"Although over 75% of children with sickle cell disease (SCD) are born in sub-Sahara where the disease highly contributes to under-5 mortality and causes life-long debilitation, evidence-based strategies to control SCD are not widely implemented in this region. Early detection of SCD by universal infant screening is a pillar of SCD control. Despite the affordability and move to adopt point-of-care (POC) SCD screening assays in sub-Sahara Africa, the absence of screening information management and communication systems (SIMCS) impedes standardized, systematic, coordinated, nationwide SCD screening programs. The long-term goal of the proposed research is to develop a SCD SIMCS that will enable universal SCD screening in the sub-Sahara African setting. The objective is to test and optimize a custom SCD SIMCS app and digital network to facilitate SCD screening and then evaluate its impact on access to SCD screening and care and on clinical outcomes of children with SCD in Uganda. The central hypothesis is that the SCD SIMCS will facilitate accurate and coordinated POC SCD screening that is accessible at health centers in urban and rural Uganda. The rationale is to build a custom SCD SIMCS on existing nationwide digital and health infrastructure in Uganda to standardize use of affordable POC assays at health centers nationwide. The central hypothesis will be tested by pursuing two specific aims: 1) Develop and evaluate a four-module ≥3G cell phone app for a novel SCD SIMCS (R21 Phase); 2) Evaluate the impact of the SCD SIMCS on access to screening and care and outcomes of children with SCD (R33 Phase). The investigators will pursue these aims using an innovative combination of software design and re-organization of SCD screening workflows. These include assembly of off-the-shelf software that is compatible with iOS and Android operating systems to reliably, accurately, and handily capture, interpret, transmit, and retrieve\u002Fplayback information for patient's IDs, test results, salient clinical events, and education. The novel screening workflows are expected to dramatically reduce the cost and increase access to SCD screening and care. The proposed research is significant, because it will determine how to use POC SCD screening assays on a large nationwide scale. It will also enable coordination of evidence-based care and continuity of care between primary and specialist providers and longitudinally over the patient's lifetime - a critical aspect in controlling this life-long disease. The SCD SIMCS will also facilitate real time data management for research and policy for SCD control. The expected immediate outcome of this research is a SCD SIMCS that optimally functions on the digital and health infrastructure in Uganda and demonstration of its impact on access to SCD screening and care and on clinical outcomes of children with SCD. The expected long-term outcome is that the SCD SIMCS will be adopted, integrated, and scaled-up in the health systems of Uganda and other sub-Sahara Africa countries, particularly those where the POC assays have already been adopted as the national standard of SCD screening. If effective, the SCD SIMCS will have an important positive impact because it will reduce the cost of SCD screening, take screening services and evidence-based care closer to rural communities where the majority of children in sub-Sahara Africa live, and, ultimately, save millions of children from preventable and disability death.",[27],"2024-08-20",{"date":207,"type":32},"2024-08-22",{"date":209,"type":21},"2024-08-21",{"date":211,"type":21},"2028-07-31",{"name":38,"class":39},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":16,"sex":17,"minAge":221,"maxAge":18,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100489985","impact-of-a-community-based-engagement-program-focused-on-adolescents-with-epilepsy-100489985","NCT05660239","Impact of a Community Based Engagement Program Focused on Adolescents With Epilepsy","Epilepsy in Uganda: Clinical Characterization and Co-morbidities, Their Relation to Stigma Among Adolescents and Impact of a Community-based Engagement Program","AWE-Change","Inclusion Criteria:\n\nAdolescent with epilepsy residing in Wakiso district\n\n* Between the ages 10-18 years\n* A resident of Wakiso district, Uganda for the previous six months\n* Confirmed diagnosis for epilepsy as per the International League Against Epilepsy definition\n* Provide written assent to participation in the study\n* With a caregiver willing to provide written informed consent as well as detailed history regarding them.\n* Willing to participate in all the required program activities with his\u002Fher caregiver\n\nExclusion Criteria:\n\nAdolescent with epilepsy residing in Wakiso district who\n\n* Does not have the time or interest to participate in the community engagement program\n* Has had exposure to a similar previous community engagement program\n* Is unable to fully understand what is required of him\u002Fher in the study and engage consistently throughout the whole community engagement program","10 Years",{"count":223,"type":21},70,[24],"The goal of this community based observation study is to co-create solutions that empower people to make informed decisions about epilepsy, reduce stigma, and promote community health among the adolescent population living with epilepsy in Uganda.\n\nThe main objectives of the study are to:\n\nGoal 1: Co-create a unique patient-community engagement program (CEP) to reduce stigma on epilepsy among adolescents and their caregivers in Uganda based on understanding of the illness.\n\nGoal 2: Evaluate the impact of this CEP to reduce stigma on epilepsy among adolescents and their caregivers in Uganda, based on understanding of the illness.\n\nStudy participants together with the relevant community stakeholders will co-design feasible communication and activity-based change projects that are based on both cultural and scientific norms, to reduce epilepsy stigma in the community Researchers will then compare the Quality of Life, Attitudes and Beliefs about Living with Epilepsy scores (as a surrogate of stigmatizing beliefs and practices among community members) and the Kilifi Stigma Scale scores in two parishes (urban and rural) to see if there is improvement in these assessments scores following the implementation of the community change projects.",[227],"Epilepsy","2023-08-30",{"date":230,"type":32},"2023-09-05",{"date":232,"type":21},"2024-03",{"date":234,"type":21},"2026-09",{"name":38,"class":39},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":16,"sex":17,"minAge":244,"maxAge":152,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":4},"100509125","phase-1-solidaritytokomeza-ebola-trial-100509125","NCT05909358","Solidarity\u002FTokomeza Ebola Trial","A Phase I\u002FII Randomized Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Sudan Ebolavirus Vaccines in Uganda","TOKOMEZA","Inclusion Criteria:\n\nPhase 1\n\n* Healthy volunteers aged 18-50 years from study communities\n* Healthy volunteers with a permanent home address\n* Able and willing to complete and provide written informed consent. In case the participant cannot read or write, the procedures must be explained to him\u002Fher and informed consent must be witnessed by a literate third party not involved with the conduct of the study\n* Participant must pass the informed consent test of understanding (TOU)\n* Participant must be healthy in the investigator's clinical judgement on the basis of medical history, physical examination, vital signs and point of care tests (where applicable) performed at screening\n* If female of child-bearing potential and heterosexually active, practice of adequate contraception for 28 days prior to injection, negative pregnancy test on the day of vaccination, and agreement to continue adequate contraception until 90 days after vaccination\n* Male participants are eligible to participate in the study if they agree to use a male condom during any heterosexual intercourse with a female of childbearing potential until 90 days after vaccination\n\nPhase 2\n\n* Healthy volunteers aged 6 years-65 years from study communities. Individuals with comorbidities assessed as stable will be allowed to participate\n* With a permanent home address\n* Able and willing to complete and provide written informed consent or assent as applicable. In case the participant cannot read or write, the procedures must be explained to him\u002Fher, and informed consent must be witnessed by a literate third party not involved with the conduct of the study.\n* Participant must pass the informed consent or assent test of understanding (TOU)\n* Participant must be healthy according to the investigator's clinical judgement on the basis of medical history, physical examination, vital signs and point of care tests (where applicable) performed at screening\n* If female of child-bearing potential and heterosexually active, practice of adequate contraception for 28 days prior to injection, negative pregnancy test on the day of vaccination, and agreement to continue adequate contraception until 180 days after vaccination\n* Male participants are eligible to participate in the study if they agree to abstain from any heterosexual intercourse with a female of childbearing potential or must agree to use a male condom\n\nExclusion Criteria:\n\nPhase 1\n\n* History of confirmed ebola virus diseases (SUDV, EBOV or BUDV)\n* Unwillingness of female participants to use effective contraception\n* Participation in an interventional clinical trial within 90 days of participation in this trial\n* Prior vaccination with any Ebola vaccine\n* Breastfeeding or planning to conceive within 2 months following study vaccination\n* Has history of fever (\\>100.4ºF\u002F38.0ºC) within 48 hours prior to enrolment into the study\n* Received systemic corticosteroids exceeding physiologic replacement doses (\\~5 mg\u002Fd prednisone equivalent) within 14 days prior to study entry\n* Received any live virus vaccine within 30 days or any non-live virus vaccine within 14 days prior to study entry\n* Has a known allergy\u002Fsensitivity or contraindication to investigational vaccines or its\u002Ftheir excipients?\n* History of malignancy ≤5 years\n* Major surgery within the 4 weeks prior to screening or planned major surgery through the course of the study (from screening until completion of the study)\n* Presence of any condition that can interfere with the subject's participation for the full duration of the trial.\n* HIV positive\n* Hepatitis B positive\n\nPhase 2\n\n* History of confirmed SUDV\n* Unwillingness of female participants to use effective contraception\n* Participation in an interventional clinical trial within 90 days of start of this trial\n* Prior vaccination with any Ebola vaccine\n* Breastfeeding or planning to conceive within 2 months following study vaccination\n* Has history of fever (\\>100.4ºF\u002F38.0ºC) within 48 hours prior to vaccination\n* Received systemic corticosteroids exceeding physiologic replacement doses (\\~20 mg\u002Fd prednisone or equivalent) for 14 days within a month prior to study entry.\n* Immunosuppressive medication within 3 months\n* Received any live virus vaccine within 30 days or any non-live virus vaccine within 14 days prior to study entry\n* Has a known allergy\u002Fsensitivity or contraindication to investigational vaccines or its\u002Ftheir excipients?\n* History of malignancy ≤5 years\n* Major surgery within the 4 weeks prior to screening or planned major surgery through the course of the study (from screening until completion of the study)\n* Presence of any condition that can interfere with the subject's participation for the full duration of the trial","6 Years",{"count":246,"type":21},2121,[248,53],"PHASE1","The TokomezaPlus Ebola trial is a phase I\u002FII double blind randomised clinical trial designed to assess the safety and immunogenicity of candidate SUDV vaccines in Uganda during the inter outbreak period. Uganda is prone to Ebola virus disease outbreaks especially those caused by the Ebola Sudan (SUDV) species. TokomezaPlus Ebola Vaccine trial protocol has two main components: a) Safety b) Immunogenicity and is designed to create a living protocol that will be used to study the safety and immunogenicity of SUDV-candidate vaccines in the East African EVD-prone countries.",[251],"Sudan Ebola Virus Vaccines","2023-06-08",{"date":254,"type":32},"2023-06-18",{"date":256,"type":21},"2023-07",{"date":258,"type":21},"2027-09",{"name":38,"class":39},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":40},"100445802","phase-3-an-enhanced-package-of-care-to-reduce-reduce-mortality-in-advanced-hiv-disease-100445802","NCT05085171","An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease","A Community-based Phase III, Cluster Randomized Trial of Point-of-care CD4 Testing and Enhanced Screening and Prophylaxis in Advanced HIV Disease","ENCORE","Inclusion Criteria:\n\n* Age \\>18 years\n* CD4\\\u003C200 cells\u002FµL\n* Ability and willingness to give informed consent for the enhanced package of care arm.\n\nExclusion Criteria:\n\n* Known virologic suppression (viral load \\\u003C1000 copies\u002FmL) within prior 3 months\n* Cannot or unlikely to attend regular clinic visits",{"count":269,"type":21},2400,[54],"A community-based Phase III, cluster randomized trial that seeks to determine the 24 week survival with retention in care of point of care CD4 testing with visitect and an enhanced package of screening and prophylaxis for opportunistic infections among patients with advanced HIV disease.",[273],"The Study Will Focus on Assessing the Survival Benefit on an Enhanced Package of Care for Patients With Advanced HIV Disease","2022-07-09",{"date":276,"type":32},"2022-07-12",{"date":278,"type":32},"2022-05-04",{"date":280,"type":21},"2027-09-01",{"name":38,"class":39},""]